MHRA approves Zolbetuximab for the treatment of Claudin18.2+ve, HER2neg gastric/GEJ cancer August 21, 2024
Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer August 21, 2024
